

# TiCARos

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	TiCARos
○ Representative	Jaewon Lee
○ Establishment year	2018
○ Specialized Field	Next Generation CAR-T Therapy
○ Address	sungsuAKvalley 1102, 76 Yeonmujang-gil, Seongdong-gu, Seoul, Republic of Korea
○ Home page	- <b>Homepage:</b> <a href="http://www.ticaros.com">www.ticaros.com</a>
○ Enterprise Brief Introduction	<p>TiCARos develops matchless CAR-T and cell therapeutics for cancer treatment, by leveraging accumulated experiences and technologies of the immunologists at Seoul National University, College of Medicine. We hope that these efforts will lead to a novel breakthrough in treatment of not only intractable hematologic malignancies but also of advanced solid tumors.</p> <p>We have three platform technologies to overcome the limitations of CAR-T therapy, and we are working on three pipelines to treat blood and solid tumors.</p> <ul style="list-style-type: none"> <li>- <b>Converter CAR:</b> Technology for strengthening immune activities of T cells themselves</li> <li>- <b>CLIP CAR:</b> Technology to improve effectiveness of CAR-T therapy by changing CAR backbone</li> <li>- <b>Switchable CAR molecule:</b> Switchable CAR technology improves the safety of CAR-T treatments</li> </ul>
○ Product and Pipeline Introduction	<ul style="list-style-type: none"> <li>● <b>TC011 (CD19 CLIP CAR-T)</b> <ul style="list-style-type: none"> <li>- Targeting Lymphoma</li> <li>- Enhancement of T cell-APC interaction with CAR backbone modification</li> <li>- In-vivo experiments show full tumor regression even in doses that commercial products do not show therapeutic effects.</li> </ul> </li> <li>● <b>TC003 (B7H3 antibody applied)</b> <ul style="list-style-type: none"> <li>- Strategies to overcome the heterogeneity of tumor antigens</li> <li>- Targeting solid cancer with self-made antibody</li> <li>- CLIP and Converter technologies will be applied to overcome immune resistance of tumors</li> </ul> </li> </ul>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ul style="list-style-type: none"> <li>● 2014-2017 Converter CAR Patent Registration</li> <li>● 2020 CLIP CAR Patent Application</li> <li>● 2019 Series A,B funding(KRW 8.1 bil)</li> </ul>